权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

SWOG Institutional Grant

SWOG 机构补助金

基本信息

批准号：
7404450
负责人：
VERNON K. SONDAK
金额：
--
依托单位：
H. LEE MOFFITT CANCER CTR & RES INST
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-06-16 至 2009-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7404450
关键词：
1-Phosphatidylinositol 3-Kinase Acute Acute leukemia Address Admission activity Adult Adverse effects Adverse event Affect Agreement Ambulatory Care Facilities American Cancer Society Anaplastic astrocytoma Animal Model Anniversary Ansamycin Antineoplastic Antibiotic Antigen-Presenting Cells Apoptosis Archives Area Arsenic Trioxide Arts Award B-Cell Lymphomas BMS-188797 Back Baptist Church Basic Science Beds Behavior Behavioral Bevacizumab/Capecitabine/Oxaliplatin Binding Biology Blood Bone Diseases Bortezomib Boston Brain Neoplasms Breast Breast Cancer Treatment Budgets CD4 Positive T Lymphocytes Calendar Cancer Biology Cancer Burden Cancer Center Cancer Control Cancer Control Research Cancer Control Research Program Cancer Patient Cancer Prevention Intervention Cancer Therapy Evaluation Program Cantor Capecitabine/Irinotecan Carboplatin Caregivers Caribbean natives Caribbean region Caring Case Study Cell Communication Cell Cycle Regulation Cell Line Cell Therapy Cell physiology Cells Certification Cessation of life Cetuximab Charge Chemotherapy-Oncologic Procedure Chest Cigarette Cisplatin Clinic Clinical Clinical Data Clinical Investigator Clinical Pharmacology Clinical Research Clinical Research Associate Clinical Treatment Clinical Trials Closure Cognitive Therapy Collaborations Collection Colorectal Cancer Communication Community Clinical Oncology Program Complementary DNA Comprehensive Cancer Center Computer software Conduct Clinical Trials Consensus Consult Core Facility Correlative Study Country County Coupled Credentialing Cross Presentation Cultured Cells Cutaneous Cutaneous Melanoma Cyclin-Dependent Kinases Cyclins Cyclophosphamide DNA Microarray Chip DNA Microarray format Daily Data Data Collection Databases Defect Dendritic Cells Deposition Depth Development Dexamethasone Dexamethasone/Doxorubicin/Vincristine Discipline of Nursing Disease Disorder by Site Disruption Distress District of Columbia Doctor of Medicine Doctor of Philosophy Documentation Dominant-Negative Mutation Dose Doxorubicin Drug Delivery Systems Drug Kinetics Drug resistance ERBB2 gene ERCC1 gene Early Diagnosis Economics Education Educational Activities Elderly Electroporation Eligibility Determination Employee Engineering Enrollment Ensure Etiology Evaluation Excision Repair Exercise Facility Construction Funding Category Faculty Fanconi&apos s Anemia Farnesyl Transferase Inhibitor Fatigue Fellowship Fertility Florida Flow Cytometry Focus Groups Fostering Funding Gastrointestinal Stromal Tumors Gefitinib Gene Expression General Population Genes Genomics Geography Goals Grant Granulocyte-Macrophage Colony-Stimulating Factor Group Meetings Growth Health Insurance Portability and Accountability Act Health Sciences Health system Hematology Hemoglobin concentration result Histone Deacetylase Histone Deacetylase Inhibitor Home environment Hospitals Housing Human Ifosfamide Image Imatinib mesylate Immune Immune system Immunity Immunology Immunotherapy In Vitro Incidence Individual Individual Differences Informatics Information Systems Informed Consent Inhibition of Apoptosis Inpatients Institutes Institution Interleukin-12 Interleukin-2 Intervention Island Karenitecin LY294002 Laboratories Laboratory Research Laboratory Study Lasers Lead Leadership Leukemic Cell Limb structure Liquid substance Local Area Networks Location Lung Lymphocyte Lymphoma MAP Kinase Gene MS-275 Malignant - descriptor Malignant Neoplasms Malignant neoplasm of brain Malignant neoplasm of gastrointestinal tract Malignant neoplasm of kidney Malignant neoplasm of lung Malignant neoplasm of prostate Mantle Cell Lymphoma Marrow Measures Mediating Medical Medical Oncology Medical center Melissa Melphalan Membrane Mentorship Metastatic Neoplasm to the Leptomeninges Metastatic Renal Cell Cancer Methods Microinjections Microscope Microscopy Minority Mission Molecular Molecular Immunology Molecular Profiling Monitor Morbidity - disease rate Multi-Institutional Clinical Trial Multiple Myeloma Mus Myelogenous Myeloid Leukemia Myeloproliferative disease N(delta)-acetylornithine, -isomer N-dodecanoylglutamic acid, -isomer, sodium salt NF-kappa B National Cancer Institute Neuraxis Neutropenic Enterocolitis New Agents New Approaches to Brain Tumor Therapy Consortium Newly Diagnosed Non-Hodgkin&apos s Lymphoma Non-Small-Cell Lung Carcinoma None or Not Applicable Nuclear Numbers Nurses Nursing Research Nursing Staff Oligonucleotides Oncogenic Oncology Group Outpatients Pain Palliative Care Pathology Pathway interactions Patient Care Patient Care Team Patient Monitoring Patients Pattern Personal Satisfaction Persons Pharmaceutical Preparations Pharmacodynamics Pharmacology Phase Phase I Clinical Trials Phase I/II Trial Phase II Clinical Trials Phase III Clinical Trials Phenotype Physician Executives Physicians Pilot Projects Plants Population Population Growth Postdoctoral Fellow Preclinical Testing Predisposition Preparation Prevalence Prevention Primary carcinoma of the liver cells Principal Investigator Printing Process Prognostic Factor Program Research Project Grants Progress Reports Proteasome Inhibition Proteasome Inhibitor Protein Overexpression Protein-Serine-Threonine Kinases Proto-Oncogene Proteins c-akt Protocol Compliance Protocols documentation Psychological Factors Psychological adjustment Publications Puerto Rico Purpose Quality of life RRM1 gene Randomized Controlled Clinical Trials Range Rate Recording of previous events Recruitment Activity Recurrence Refractory Registered nurse Regulation Relapse Renal carcinoma Reporting Research Research Activity Research Design Research Ethics Committees Research Infrastructure Research Institute Research Personnel Research Project Grants Research Subjects Resected Resistance Resources Rest Review Literature Rifabutin Risk Role Sampling Schedule Science Scientist Screening for cancer Screening procedure Secondary to Services Severities Sex Functioning Shared Resource Cancer Center Site Slide Small Inducible Cytokine A3 Societies Solid Solid Neoplasm Source South America Southwest Oncology Group Specialist Specimen Staging Standards of Weights and Measures Stromal Cells Support of Research Symptoms System T-Cell Activation T-Cell Lymphoma T-Lymphocyte Taxane Compound Taxes Techniques Teleconferences Testing Thalidomide Therapeutic Therapeutic Studies Therapy Clinical Trials Time Tipifarnib Tissues Topoisomerase Topoisomerase Inhibitors Topoisomerase-II Inhibitor Toxic effect Training Training and Education Transgenic Organisms Translating Translational Research Translations Transplantation Travel Treatment Protocols Tumor Antigens Tyrosine USA Georgia Underserved Population United States United States National Institutes of Health Universities Update Urogenital Cancer Valproic Acid Vascular Endothelial Growth Factors Vision Visit Week Western Asia Georgia Woman Work Writing ZD1839 (IRESSA)Zarnestra alpha-difluoromethyl-DOPA, -isomer alpha-methylornithine dihydrochloride, -isomer anticancer research base bevacizumab cancer care cancer immunotherapy cancer prevention cancer therapy cell growth chemotherapy chronic leukemia cognitive function cohort computer science concept conditioning cytokine dalton data management day design digital docetaxel experience falls farnesylation follow-up foot gastrointestinal gemcitabine gene repair gene therapy human FRAP1 protein human RRM1 protein human TOP1 protein human prostaglandin D2 receptor human tissue improved in vivo inhibitor/antagonist innovation insight interdisciplinary approach interest investigator training leukemia liver biopsy loris mTOR Inhibitor mTOR inhibition malignant breast neoplasm medical schools medical specialties melanoma member metastatic colorectal molecular dynamics molecular imaging molecular oncology mouse model neoplastic cell neuro-oncology novel novel therapeutics oncology outreach oxaliplatin patient safety pre-clinical preclinical study prevent progesterone 11-hemisuccinate-(2-iodohistamine)programs protein farnesyltransferase protocol development psychologic psychosocial quality assurance research facility response sarcoma small molecule stress management symptom management taxane temozolomide tool tool development translational study tumor tumor growth tumorigenesis vector

项目摘要

DESCRIPTION (provided by applicant): The H. Lee Moffitt Cancer Center and Research Institute (HLMCC), founded by the Florida State legislature in 1981, is dedicated to the prevention and cure of cancer. Situated in West Central Florida, it is ideally situated to translate novel scientific discoveries into state-of-the-science clinical trials. Commensurate with the unprecidented population growth in the state of Florida, the HLMCC presently ranks third in the country in numbers of ambulatory cancer patient visits. It is the only single-site National Cancer Institute-designated comprehensive cancer center in the state of Florida, a recognition it received in 2001 and receives patient referrals from entire Southeast of the United States, in addition to Puerto Rico and Central and South America. In 2005 the HLMCC investigators overwhelmingly decided to transfer co-operative group participation, from the Eastern Cooperative Group to the Southwest Oncology Group (SWOG): this decision was based on geography, and the recruitment of investigators with deep experience in SWOG clinical research activity. As part of the centers' mission to provide total cancer care, Moffitt has developed an extensive affiliate network throughout the states of Florida and Georgia, in addition to the island of Puerto Rico involving twelve institution and over 200 credentialed investigators. This affiliate network will be an integral part of accrual to SWOG trials, and the Moffitt SWOG office will work closely with the HLMCC affiliate office to guide the ongoing credentially, monitoring and education of staff. Key investigators have been identified in each of the disease related tumor programs at the HLMCC, with experience in the design, and writing of investigator-initiated clinical trials, many of whom have NCI grant funding: these investigators will provide the leadership and of the timely activation and accrual of SWOG trials within HLMCC and throughout its' affiliate network, in addition to providing active participation in the biannual SWOG meetings. Thus, through robust participation in the active design and accrual to SWOG cooperative trials, we believe that the HLMCC will advance its goal of providing total cancer care to the Southeast United States, and continue to pursue its' stated mission of curing and preventing cancer as a cause of illness and death.

描述（由申请人提供）：